feed,title,long_url,short_url
Nasdaq,Capital Markets Look for Direction,https://www.nasdaq.com/articles/capital-markets-look-for-direction-2021-04-12,https://j.mp/3mEgjT7
Nasdaq,Add Up The Parts: PXE Could Be Worth $16,https://www.nasdaq.com/articles/add-up-the-parts%3A-pxe-could-be-worth-%2416-2021-04-12,https://j.mp/3a4zdgM
Nasdaq,"Today's Mortgage Rates -- April 12, 2021: Rates Mixed",https://www.nasdaq.com/articles/todays-mortgage-rates-april-12-2021%3A-rates-mixed-2021-04-12,https://j.mp/3tbwsSD
Nasdaq,Implied QQQJ Analyst Target Price: $36,https://www.nasdaq.com/articles/implied-qqqj-analyst-target-price%3A-%2436-2021-04-12,https://j.mp/3a0sRiw
Nasdaq,Wall Street Foresees Lower Opening,https://www.nasdaq.com/articles/wall-street-foresees-lower-opening-2021-04-12,https://j.mp/3mH5AHK
Nasdaq,Bay Street Likely To Open On Cautious Note,https://www.nasdaq.com/articles/bay-street-likely-to-open-on-cautious-note-2021-04-12,https://j.mp/3mEgjCB
Nasdaq,Sage Therapeutics : Phase 2 Study Of SAGE-324 In Essential Tremor Meets Primary Endpoint,https://www.nasdaq.com/articles/sage-therapeutics-%3A-phase-2-study-of-sage-324-in-essential-tremor-meets-primary-endpoint,https://j.mp/3a3tdVH
Nasdaq,Adamis To Resubmit NDA For ZIMHI Within 45 Days - Quick Facts,https://www.nasdaq.com/articles/adamis-to-resubmit-nda-for-zimhi-within-45-days-quick-facts-2021-04-12,https://j.mp/3dZi6xY
Nasdaq,FibroGen: Pamrevlumab Gets FDA's Fast Track Designation To Treat Duchenne Muscular Dystrophy,https://www.nasdaq.com/articles/fibrogen%3A-pamrevlumab-gets-fdas-fast-track-designation-to-treat-duchenne-muscular,https://j.mp/3sfhTMm
